博腾股份（股票代码：300363）成立于2005年，是国内领先的医药合同定制研发及生产企业（CDMO），我们为全球药企、新药研发机构等提供从临床早期研究直至药品上市全生命周期所需的化学原料药、化学制剂和生物药的定制研发和生产服务。作为一家国家高新技术企业，博腾为全球知名药企及药物研发机构长期提供卓越的端到端CDMO服务，我们的研发、生产和运营机构遍及中国、美国、比利时、瑞士和英国。

博腾致力于成为全球最开放、最创新、最可靠的制药服务平台，让好药更早惠及大众。我们拥有领先的研发技术平台能力、完善的质量管理体系、EHS管理体系和良好的交付记录，生产基地先后通过NMPA、FDA、PMDA、EMA和WHO权威认证。我们开放近十余年服务全球知名药企的经验和国际一流CDMO平台来积极支持国内药企的发展，加速新药上市进程，全面为国内化学和生物制药、药物研发机构等提供创新药CMC服务、MAH委托生产服务、临床试验服务、创新药中间体、原料药到制剂的定制研发及生产服务和生物基因与细胞CDMO服务。

With over 3,000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.

Our Process Technology Centers and USFDA/EMA/PDMA/NMPA/WHO-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus over 500 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for your unique project requirements.

We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and Enabling public’s early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and compliance with global Quality and EHS standards. By efficiently advancing development and enabling commercialization of multiple high-impact medicines, Porton is proud to have earned the trust of some of the world’s leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia.